Cilento, Michael A. http://orcid.org/0000-0003-2216-5650
Sweeney, Christopher J. http://orcid.org/0000-0002-0398-6018
Butler, Lisa M. http://orcid.org/0000-0003-2698-3220
Funding for this research was provided by:
The University of Adelaide
Article History
Received: 19 March 2024
Accepted: 22 May 2024
First Online: 8 June 2024
Declarations
:
: Michael A Cilento: declares no potential competing interests. Christopher J Sweeney: Consulting or Advisory Role: Sanofi, Janssen, Astellas Pharma, Bayer, Genentech, Pfizer, Lilly, MDS, Point Biopharma; Research Funding: Janssen Biotech (Inst), Astellas Pharma (Inst), Sanofi (Inst), Bayer (Inst), Patents, Royalties, Other Intellectual Property: Parthenolide (Indiana University): dimethylaminoparthenolide (Leuchemix); Exelixis: Abiraterone plus cabozantinib combination; FRAS1 SNP and tristetraprolin as biomarkers of lethal prostate cancer. Stock or Other Ownership: Leuchemix. Lisa M Butler: declares no potential competing interests.